Rabbit anti-Human LILRA2/CD85h Monoclonal Antibody for IF/ICC, FC - Q8N149

Core Product Specifications and Parameters

Biological Background: LILRA2/CD85h Function and Localization

• LILRA2 is a type I transmembrane receptor belonging to the leukocyte immunoglobulin-like receptor (LILR) family; it is also referred to as CD85h, immunoglobulin-like transcript 1 (ILT-1), or leukocyte immunoglobulin-like receptor 7 (LIR-7).
• It functions as a pattern recognition receptor in innate immunity, specifically binding to N-terminally truncated immunoglobulin molecules generated by bacterial and fungal proteases from pathogens such as Legionella pneumophila, Mycoplasma hyorhinis, Streptococcus pneumoniae, Staphylococcus aureus, and Candida albicans.
  Related references:
  PMID:27572839
• LILRA2 engagement on neutrophils triggers cellular activation, while on monocytes it induces the secretion of cytokines and chemokines (e.g., CSF2, IL6, CXCL8) and downregulates TLR4-mediated responses to bacterial LPS.
  Related references:
  PMID:22479404
• In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4, and leukotriene C4.
  Related references:
  PMID:12529506
• LILRA2 does not interact with classical MHC class I molecules, distinguishing it from some other LILR family members.
  Related references:
  PMID:19230061
• Subcellular localization includes the cell membrane and secreted isoforms, reflecting the existence of alternative splicing variants and soluble forms that may modulate immune responses.
• Expression is restricted primarily to innate immune cells: detected at the protein level on peripheral blood monocytes, neutrophils, basophils, and eosinophils, with little or no expression on lymphocytes and dendritic cells.
• The protein is glycosylated, contains conserved disulfide bonds, and is subject to post-translational modifications such as nitration; its predicted molecular weight is approximately 53 kDa, with observed isoforms at 47–53 kDa.

Experimental Guidance and Technical Tips

• The immunogen (aa 24-449 of human LILRA2) covers the entire extracellular domain, which may enable recognition of both full-length and soluble isoforms; thus, the antibody could be suitable for detecting secreted LILRA2 in addition to membrane-bound forms.
• For flow cytometry, consider using appropriate isotype controls and titrating the antibody to achieve optimal staining on primary human innate immune cells (monocytes, neutrophils) or LILRA2-transfected cell lines.
• In immunofluorescence/ICC, since LILRA2 is a cell surface receptor, gentle fixation (e.g., 4% PFA) without permeabilization may help preserve surface staining; if intracellular staining is needed, permeabilization may be adjusted.
• As the antibody is directly conjugated to , no secondary antibody is required, reducing background and experimental steps; verify signal stability and avoid prolonged light exposure.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines IVD raw material sourcing for diagnostic manufacturers and research labs, providing a comprehensive portfolio that includes validated monoclonal antibodies, matched antibody pairs, and ancillary reagents. The Anti-LILRA2/CD85h mAb () supports innate immunity and infectious disease research applications. For bulk orders, custom conjugations, or rare target reagent sourcing, our technical team can assist in accelerating your development pipeline.